Brain aging and Alzheimer's disease, a perspective from non-human primates.

Aging (Albany NY)

Department of Pathology and Experimental Therapeutics, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.

Published: October 2024

AI Article Synopsis

  • Brain aging is analyzed by comparing macaques, baboons, and non-human primates (like chimpanzees and gorillas) to humans, revealing distinct differences in brain pathology.
  • Non-human primates mostly show mild β-amyloid deposition and tau pathology, while humans experience more severe tau-related changes early in aging, complicating cognitive functions.
  • Various neurodegenerative diseases, prevalent among aged humans, like Alzheimer's, are absent in non-human primates, indicating that humans have a uniquely severe aging process in the brain.

Article Abstract

Brain aging is compared between (macaques and baboons), non-human (chimpanzees, orangutans, and gorillas), and their close relative, humans. β-amyloid deposition in the form of senile plaques (SPs) and cerebral β-amyloid angiopathy (CAA) is a frequent neuropathological change in non-human primate brain aging. SPs are usually diffuse, whereas SPs with dystrophic neurites are rare. Tau pathology, if present, appears later, and it is generally mild or moderate, with rare exceptions in rhesus macaques and chimpanzees. Behavior and cognitive impairment are usually mild or moderate in aged non-human primates. In contrast, human brain aging is characterized by early tau pathology manifested as neurofibrillary tangles (NFTs), composed of paired helical filaments (PHFs), progressing from the entorhinal cortex, hippocampus, temporal cortex, and limbic system to other brain regions. β-amyloid pathology appears decades later, involves the neocortex, and progresses to the paleocortex, diencephalon, brain stem, and cerebellum. SPs with dystrophic neurites containing PHFs and CAA are common. Cognitive impairment and dementia of Alzheimer's type occur in about 1-5% of humans aged 65 and about 25% aged 85. In addition, other proteinopathies, such as limbic-predominant TDP-43 encephalopathy, amygdala-predominant Lewy body disease, and argyrophilic grain disease, primarily affecting the archicortex, paleocortex, and amygdala, are common in aged humans but non-existent in non-human primates. These observations show that human brain aging differs from brain aging in non-human primates, and humans constitute the exception among primates in terms of severity and extent of brain aging damage.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552644PMC
http://dx.doi.org/10.18632/aging.206143DOI Listing

Publication Analysis

Top Keywords

brain aging
28
non-human primates
16
brain
9
sps dystrophic
8
dystrophic neurites
8
tau pathology
8
pathology appears
8
mild moderate
8
cognitive impairment
8
human brain
8

Similar Publications

Translational validity of mouse models of Alzheimer's disease (AD) is variable. Because change in weight is a well-documented precursor of AD, we investigated whether diversity of human AD risk weight phenotypes was evident in a longitudinally characterized cohort of 1,196 female and male humanized APOE (hAPOE) mice, monitored up to 28 months of age which is equivalent to 81 human years. Autoregressive Hidden Markov Model (AHMM) incorporating age, sex, and APOE genotype was employed to identify emergent weight trajectories and phenotypes.

View Article and Find Full Text PDF

NOTCH3 Mutation Causes Glymphatic Impairment and Promotes Brain Senescence in CADASIL.

CNS Neurosci Ther

January 2025

Department of Neurology, Mental and Neurological Disease Research Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Aims: The aim of this study is to investigate the role of glymphatic function of cerebral autosomal dominant arteriopathy, subcortical infarcts, and leukoencephalopathy (CADASIL), the most common monogenic small vessel disease caused by NOTCH3 mutation, and to explore potential therapeutic strategies to improve glymphatic function.

Methods: We assessed glymphatic influx and efflux function in CADASIL mouse models (Notch3) and correlated these findings with brain atrophy in CADASIL patients. We also investigated the underlying mechanisms of glymphatic impairment, focusing the expression of AQP4 in astrocytic endfeet.

View Article and Find Full Text PDF

Computational simulation of cranial soft tissue expansion on the cranium during early postnatal growth in humans.

J Anat

January 2025

Department of Musculoskeletal & Ageing Science, Institute of Life Course & Medical Sciences (ILCaMS) and Human Anatomy Resource Centre (HARC), Education Directorate, University of Liverpool, Liverpool, UK.

The importance of interactions between neighbouring rapidly growing tissues of the head during development is recognised, yet this competition for space remains incompletely understood. The developing structures likely interact through a variety of mechanisms, including directly genetically programmed growth, and are mediated via physiological signalling that can be triggered by structural interactions. In this study, we aimed to investigate a different but related potential mechanism, that of simple mechanical plastic deformation of neighbouring structures of the head in response to soft tissue expansion during human postnatal ontogeny.

View Article and Find Full Text PDF

Sarcopenia and cancer cachexia are two life-threatening conditions often misdiagnosed. The skeletal muscle is one of the organs most adversely affected by these conditions, culminating in poor quality of life and premature mortality. In addition, it has been suggested that chemotherapeutic agents exacerbate cancer cachexia, as is the case of doxorubicin.

View Article and Find Full Text PDF

Introduction: The large-scale approval of anti-amyloid monoclonal antibodies for treating Alzheimer's disease (AD) has raised concerns about their safety due to treatment-emergent amyloid-related imaging abnormalities (ARIA).

Methods: We present two cases of patients diagnosed with mild cognitive impairment due to AD who were enrolled in the GRADUATE I clinical trial. They received subcutaneous gantenerumab every two weeks during the study period.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!